Article info
PDFAsthma: airways and antibodies
P16 Implications of nice guidance in england and wales on eligibility for treatment with mepolizumab and omalizumab – an ideal study analysis
Citation
P16 Implications of nice guidance in england and wales on eligibility for treatment with mepolizumab and omalizumab – an ideal study analysis
Publication history
- First published November 15, 2017.
Online issue publication
September 01, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions